Lurbinectedin in Ewing Sarcoma

Lurbinectedin in Ewing Sarcoma

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Eligibility and criteria
IRB Number:
22-020296
Eligible age range:
2 years - 30 years
Clinical trial phase:
Phase I
Phase II
Official title:
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants with Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants with Relapsed/Refractory Ewing Sarcoma

What to expect
As a participant in the research, you will:

  • Receive lurbinectedin infusions
  • Complete frequent clinic visits at CHOP
  • Have frequent blood tests, including research blood tests to measure lurbinectedin levels (pharmacokinetic studies)
  • Have periodic EKGs and echocardiograms
  • Have periodic imaging performed to evaluate your response to treatment

Related specialties

Related conditions
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.